Aminoguanidin-kezelés pozitív hatása a peroxinitrit-termelodésre és szívhipertrófiára streptozotocinnal indukált diabeteses patkányokban.

Translated title of the contribution: Aminoguanidine prevents peroxynitrite production and cardiac hypertrophy in streptozotocin-induced diabetic rats

Krisztián Stadler, Veronika Jenei, A. Somogyi, J. Jakus

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The effect and possible mechanisms of action of aminoguanidine (a preferential iNOS inhibitor) has been studied on cardiovascular damages and overproduction of reactive nitrogen species in streptozotocin-induced diabetic rats. MATERIALS AND METHODS: 40 rats were divided into five groups (control and diabetic, with or without aminoguanidine treatment, diabetic with insulin treatment) and oxidative stress parameters were examined. Tissue nitric oxide levels were determined by EPR spectroscopy, while peroxynitrite generation by a chemiluminescence method. Cardiac hypertrophy, blood metabolic parameters (blood glucose, HbA1c, fructosamine), as well as tissue protein carbonyl levels were also determined. RESULTS: Diabetic animals showed increased nitric oxide and peroxynitrite generation in the aorta along with a significant hypertrophy and protein carbonylation of the cardiac tissue. Both aminoguanidine and insulin treatment suppressed high levels of nitric oxide and peroxynitrite in the vasculature, but only aminoguanidine was able to prevent hypertrophic alterations and to reduce protein carbonylation in the heart. CONCLUSIONS: The results show that (1) aminoguanidine reduces nitric oxide production and prevents cardiac hypertrophy, (2) insulin therapy improves carbohydrate metabolism, reduces nitrosative stress but has no effect on cardiac hypertrophy. Cardiac hypertrophy in diabetes is strongly correlated with non-enzymatic glycation. Aminoguanidine prevented hypertrophy by blocking the formation of advanced glycation end products rather than via other mechanisms.

Original languageHungarian
Pages (from-to)2491-2496
Number of pages6
JournalOrvosi Hetilap
Volume145
Issue number49
Publication statusPublished - Dec 5 2004

Fingerprint

Peroxynitrous Acid
Cardiomegaly
Streptozocin
Nitric Oxide
Protein Carbonylation
Insulin
Hypertrophy
Fructosamine
Reactive Nitrogen Species
Advanced Glycosylation End Products
Carbohydrate Metabolism
Luminescence
Aorta
Blood Glucose
pimagedine
Spectrum Analysis
Oxidative Stress
Control Groups
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Aminoguanidin-kezelés pozitív hatása a peroxinitrit-termelodésre és szívhipertrófiára streptozotocinnal indukált diabeteses patkányokban. / Stadler, Krisztián; Jenei, Veronika; Somogyi, A.; Jakus, J.

In: Orvosi Hetilap, Vol. 145, No. 49, 05.12.2004, p. 2491-2496.

Research output: Contribution to journalArticle

@article{96471c0bad32467283243359e0f072a8,
title = "Aminoguanidin-kezel{\'e}s pozit{\'i}v hat{\'a}sa a peroxinitrit-termelod{\'e}sre {\'e}s sz{\'i}vhipertr{\'o}fi{\'a}ra streptozotocinnal induk{\'a}lt diabeteses patk{\'a}nyokban.",
abstract = "The effect and possible mechanisms of action of aminoguanidine (a preferential iNOS inhibitor) has been studied on cardiovascular damages and overproduction of reactive nitrogen species in streptozotocin-induced diabetic rats. MATERIALS AND METHODS: 40 rats were divided into five groups (control and diabetic, with or without aminoguanidine treatment, diabetic with insulin treatment) and oxidative stress parameters were examined. Tissue nitric oxide levels were determined by EPR spectroscopy, while peroxynitrite generation by a chemiluminescence method. Cardiac hypertrophy, blood metabolic parameters (blood glucose, HbA1c, fructosamine), as well as tissue protein carbonyl levels were also determined. RESULTS: Diabetic animals showed increased nitric oxide and peroxynitrite generation in the aorta along with a significant hypertrophy and protein carbonylation of the cardiac tissue. Both aminoguanidine and insulin treatment suppressed high levels of nitric oxide and peroxynitrite in the vasculature, but only aminoguanidine was able to prevent hypertrophic alterations and to reduce protein carbonylation in the heart. CONCLUSIONS: The results show that (1) aminoguanidine reduces nitric oxide production and prevents cardiac hypertrophy, (2) insulin therapy improves carbohydrate metabolism, reduces nitrosative stress but has no effect on cardiac hypertrophy. Cardiac hypertrophy in diabetes is strongly correlated with non-enzymatic glycation. Aminoguanidine prevented hypertrophy by blocking the formation of advanced glycation end products rather than via other mechanisms.",
author = "Kriszti{\'a}n Stadler and Veronika Jenei and A. Somogyi and J. Jakus",
year = "2004",
month = "12",
day = "5",
language = "Hungarian",
volume = "145",
pages = "2491--2496",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "49",

}

TY - JOUR

T1 - Aminoguanidin-kezelés pozitív hatása a peroxinitrit-termelodésre és szívhipertrófiára streptozotocinnal indukált diabeteses patkányokban.

AU - Stadler, Krisztián

AU - Jenei, Veronika

AU - Somogyi, A.

AU - Jakus, J.

PY - 2004/12/5

Y1 - 2004/12/5

N2 - The effect and possible mechanisms of action of aminoguanidine (a preferential iNOS inhibitor) has been studied on cardiovascular damages and overproduction of reactive nitrogen species in streptozotocin-induced diabetic rats. MATERIALS AND METHODS: 40 rats were divided into five groups (control and diabetic, with or without aminoguanidine treatment, diabetic with insulin treatment) and oxidative stress parameters were examined. Tissue nitric oxide levels were determined by EPR spectroscopy, while peroxynitrite generation by a chemiluminescence method. Cardiac hypertrophy, blood metabolic parameters (blood glucose, HbA1c, fructosamine), as well as tissue protein carbonyl levels were also determined. RESULTS: Diabetic animals showed increased nitric oxide and peroxynitrite generation in the aorta along with a significant hypertrophy and protein carbonylation of the cardiac tissue. Both aminoguanidine and insulin treatment suppressed high levels of nitric oxide and peroxynitrite in the vasculature, but only aminoguanidine was able to prevent hypertrophic alterations and to reduce protein carbonylation in the heart. CONCLUSIONS: The results show that (1) aminoguanidine reduces nitric oxide production and prevents cardiac hypertrophy, (2) insulin therapy improves carbohydrate metabolism, reduces nitrosative stress but has no effect on cardiac hypertrophy. Cardiac hypertrophy in diabetes is strongly correlated with non-enzymatic glycation. Aminoguanidine prevented hypertrophy by blocking the formation of advanced glycation end products rather than via other mechanisms.

AB - The effect and possible mechanisms of action of aminoguanidine (a preferential iNOS inhibitor) has been studied on cardiovascular damages and overproduction of reactive nitrogen species in streptozotocin-induced diabetic rats. MATERIALS AND METHODS: 40 rats were divided into five groups (control and diabetic, with or without aminoguanidine treatment, diabetic with insulin treatment) and oxidative stress parameters were examined. Tissue nitric oxide levels were determined by EPR spectroscopy, while peroxynitrite generation by a chemiluminescence method. Cardiac hypertrophy, blood metabolic parameters (blood glucose, HbA1c, fructosamine), as well as tissue protein carbonyl levels were also determined. RESULTS: Diabetic animals showed increased nitric oxide and peroxynitrite generation in the aorta along with a significant hypertrophy and protein carbonylation of the cardiac tissue. Both aminoguanidine and insulin treatment suppressed high levels of nitric oxide and peroxynitrite in the vasculature, but only aminoguanidine was able to prevent hypertrophic alterations and to reduce protein carbonylation in the heart. CONCLUSIONS: The results show that (1) aminoguanidine reduces nitric oxide production and prevents cardiac hypertrophy, (2) insulin therapy improves carbohydrate metabolism, reduces nitrosative stress but has no effect on cardiac hypertrophy. Cardiac hypertrophy in diabetes is strongly correlated with non-enzymatic glycation. Aminoguanidine prevented hypertrophy by blocking the formation of advanced glycation end products rather than via other mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=13744253074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13744253074&partnerID=8YFLogxK

M3 - Article

C2 - 15633737

AN - SCOPUS:13744253074

VL - 145

SP - 2491

EP - 2496

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 49

ER -